| Literature DB >> 32337081 |
Nandi Siegfried1, Manjulaa Narasimhan2, Carmen H Logie3, Rebekah Thomas4, Laura Ferguson5, Kevin Moody6, Michelle Remme7.
Abstract
Introduction: In January 2019, the WHO reviewed evidence to develop global recommendations on self-care interventions for sexual and reproductive health and rights (SRHR). Identification of research gaps is part of the WHO guidelines development process, but reliable methods to do so are currently lacking with gender, equity and human rights (GER) infrequently prioritised.Entities:
Keywords: diseases; disorders; epidemiology; infections; injuries; public health; study design
Mesh:
Year: 2020 PMID: 32337081 PMCID: PMC7170423 DOI: 10.1136/bmjgh-2019-002128
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Key domains that require consideration when formulating WHO recommendations
| Factor | How the factor influences the direction and strength of a recommendation |
| Quality of the evidence | The quality of the evidence across outcomes critical to decision making will inform the strength of the recommendation. The higher the quality of the evidence, the greater the likelihood of a strong recommendation. |
| Values and preferences | This describes the relative importance assigned to health outcomes by those affected by them; how such importance varies within and across populations; and whether this importance or variability is surrounded by uncertainty. The less uncertainty or variability there is about the values and preferences of people experiencing the critical or important outcomes, the greater the likelihood of a strong recommendation. |
| Balance of benefits versus harms | This requires an evaluation of the absolute effects of both benefits and harms (or downsides) of the intervention and their importance. The greater the net benefit or net harm associated with an intervention or exposure, the greater the likelihood of a strong recommendation in favour or against the intervention. |
| Resource implications | This pertains to how resource intense an intervention is, whether it is cost–effective and whether it offers any incremental benefit. The more advantageous or clearly disadvantageous the resource implications are, the greater the likelihood of a strong recommendation either for or against the intervention. |
| Priority | The problem’s priority is determined by its importance and frequency (ie, burden of disease, disease prevalence or baseline risk). The greater the importance of the problem, the greater the likelihood of a strong recommendation. |
| Equity and human rights | The greater the likelihood that the intervention will reduce inequities, improve equity or contribute to the realisation of one or several human rights as defined under the international legal framework, the greater the likelihood of a strong recommendation. |
| Acceptability | The greater the acceptability of an option to all or most stakeholders, the greater the likelihood of a strong recommendation. |
| Feasibility | The greater the feasibility of an option from the standpoint of all or most stakeholders, the greater the likelihood of a strong recommendation. Feasibility overlaps with values and preferences, resource considerations, existing infrastructures, equity, cultural norms, legal frameworks and many other considerations. |
Reproduced from the WHO 2014.1
Figure 1Hierarchical decision making algorithm to formulate research questions based on the presence and strength of a WHO recommendation, combined with the source of the question. GDG, Guidelines Development Group; GER, gender, equity and human rights; PICO, Population, Interventions, Comparison and Outcomes.
Research gaps for self-administration of injectable contraception
| Clinical, programmatic, values-based or human rights question | Current WHO recommendation | Strength of recommendation | Source or quality of evidence | Key GER considerations | Ideal study design(s) | Feasibility and practical constraints | Alternative study design | Methodological issues arising in the alternative study design | |
| Benefits versus harms | PICO: should self-administered injectable contraception be made available as an additional approach to deliver injectable contraception? | Self-administered injectable contraception should be made available as an additional approach to deliver injectable contraception. | Strong. | Moderate. | No data available from LMIC; availability, accessibility, privacy and confidentiality. | RCT conducted in LMIC with inclusion of outcomes to measure accessibility, privacy and confidentiality. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of the intervention. | Prospective non-controlled cohort study to be conducted in several low- and middle-income countries where the intervention is or will be implemented. Analysis to combine quantitative survey supplemented with focused in-depth qualitative interviews with women (both those who have used and have not used self-administered injectable contraception and including adolescent girls and young women) to explore GER outcomes of availability, accessibility, privacy and confidentiality. Cost analyses can be nested in the cohort study. | |
| Values and preferences | Is there an impact of differences between groups of women (eg, age, socioeconomic and occupational status) on their values and preferences with respect to self-administration of injectable contraception? | Not applicable. | Not applicable. | GDG. | Accessibility, privacy and confidentiality, non-discrimination. | Cross-sectional study of women using injectable contraception to evaluate associations between characteristics and use, or willingness to use. | A survey may not provide an objective measure or a true reflection of behaviours if driven by questions requiring socially acceptable responses. | This is a feasible study design but could be supplemented with diary collection of data as greater privacy and less likely for social desirability to influence self-recording. Partnering with women who have used or are willing to self-administer injectable contraception is important to identify critical and non-judgmental questions. | |
| What happens after women discontinue use of self-injectable contraception – do they use other methods? | Not applicable. | Not applicable. | GDG. | Accessibility. | National pharmacy or clinic-based registry of women using self-administered injectable contraception. | Registries can be costly to establish, maintain and monitor. A registry requires political will and capacity to provide effective data to inform decisions. | Convenience sample and survey of women attending family planning clinics to elucidate their prior modes of contraception and reasons for discontinuation. | ||
| What is the impact of stigma on the choice of self-administration of injectable contraception? | Not applicable. | Not applicable. | GDG and survey. | Accessibility, privacy and confidentiality and non-discrimination. | Qualitative study of interviews of women self-administering injectable contraception to elucidate their experiences and observations. | This is a feasible study. | Not applicable. | ||
| What are the optimal models of information provision for awareness raising and increasing knowledge of self-administration of injectable contraception? | Not applicable. | Not applicable. | GDG and survey. | Accessibility, the right to seek, receive and impart information. | Comparative effectiveness research of different models of information provision, optimally in an RCT. | This will first require development of models of dedicated information provision and health literacy (eg, telephonic, internet, posters and counselling) prior to experimental testing. | Exploratory qualitative interviews with women self-administering or willing to self-administer to identify their knowledge, attitudes and understanding of injectable contraception are required to inform models of information provision. | ||
| Human rights and equity | What implementation measures can ensure that inequity is reduced or minimised when self-administration is introduced? | Not applicable. | Not applicable. | GDG. | Non-discrimination. | Comparative effectiveness research of different models of implementation, optimally in a cluster RCT. | An RCT of models of implementation may be very costly due to the complex nature of implementation strategies that are dependent on the setting, type of provider and training required, and ensuring fidelity to the intervention. | Descriptive case studies of demonstration projects using different strategies to implement injectable contraception in programmes in several countries to indicate optimal measures to ensure equitable access and to formulate lessons learnt for scale-up elsewhere | |
| Acceptability | Is there an impact of differences between healthcare providers (eg, age, income status of country, private/public sector) on the acceptability of self-administration of injectable contraception? | Not applicable. | Not applicable. | GDG. | Acceptability and accessibilty. | Cross-sectional study of healthcare providers to evaluate associations between characteristics and willingness to prescribe and provide injectable contraception for self-administration. | A survey may not provide an objective measure or a true reflection of behaviours if driven by questions requiring socially acceptable responses. | This is a feasible study design but could be supplemented with focus groups or qualitative interviews. | |
| What is the scale and consequence of incorrect use of self-administration? | Not applicable. | Not applicable. | GDG. | Accountability. | National pharmacy or clinic-based registry of women using self-administered injectable contraception. | Registries can be costly to establish, maintain and monitor. A registry requires political will and capacity to provide effective data to inform decisions. | Sentinel (active) surveillance through monitoring and evaluation of adverse effects and adverse events at clinic or provider level embedded in local and national quality assurance programmes. | ||
| Resource use | What are the user and provider costs of self-administration (as well as out-of-pocket expenditures), compared with provider-based administration? | Not applicable. | Not applicable. | GDG and survey. | Accessibility. | Empirical costing studies to estimate user and provider costs, and financing sources for each (users pay or health system pays) | This is a feasible study but can be costly to conduct across a representative sample of users and facilities. | This is feasible but could be supplemented by modelling based on the existing empirical cost data, cost structures and expert consultation on expected variation in parameters. | |
| What is the cost-effectiveness of self-administration, compared with provider-based administration? | Not applicable. | Not applicable. | GDG. | Accessibility. | Modelling studies of cost- effectiveness across broader range of settings, taking both a healthcare provider and societal perspective. | This is a feasible study but its quality and usefulness depends on the reliability of the parameters for unit costs and effectiveness, which would be drawn from costing studies (noted above) and RCTs. It will also require more long-term modelling to capture downstream effects on the types of contraceptives self-injecting women switch to compared with provider-based injecting women. | |||
| What is the environmental impact of disposal of self-administered injectable oral contraception? | Not applicable. | Not applicable. | GDG. | Accountability. | Collection and collation of reports from environmental regulatory bodies documenting scale and impact of medical waste and household waste. | Regulatory agencies are unlikely to differentiate between whether injectable contraceptives present in waste are sourced directly from clinics or from the homes of users. | A qualitative household diary study of women who self-inject in which they record waste from the packaging and their management of it. This could be delivered with the injectable packaging and women can return it when collecting their next prescription. | ||
GDG, Guideline Development Group; GER, gender, equity and human rights; RCTs, randomised controlled trials.
Research gaps for self-collection of STI samples
| Clinical, programmatic, values-based or human rights question | Current WHO recommendation | Strength of recommendation | Source or quality of evidence | Key GER considerations | Ideal study design(s) | Feasibility and practical constraints | Alternative study design | Methodological issues arising in the alternative study design | |
| Benefits versus harms | PICO: should self-collection of samples for STIs be made available as an additional approach to deliver STI testing services? | Self-collection of samples for | Strong. | Moderate. | No data from LMIC. Availability and accessibility. | RCT conducted in LMIC with inclusion of outcomes to measure availability and accessibility. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of the intervention. | Prospective non-controlled cohort study to be conducted in several LMICs where the intervention is or will be implemented. Analysis to combine quantitative survey supplemented with focused in-depth qualitative interviews with general population (with attention given to ensure sampling of vulnerable populations) to explore GER outcomes of availability and accessibility. Cost analyses can be nested in the cohort study. | |
| Self-collection of samples for | Conditional. | Low. | Availability, accessibility and acceptability. | Randomised controlled trial specific to self-collection of these organisms. | This is a feasible design. | ||||
| What is the impact of self-sampling for STIs on partner screening? | GDG. | Privacy and confidentiality. | Randomised controlled trial with uptake of partner screening included as an outcome. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of the intervention. | Cross-sectional study of women who respond to results following STI self-collection to ascertain how many have notified their partners to be screened, and of those how many partners have gone for screening. Acceptability of screening for partners, and availability and accessibility of partner screening will be important to measure. | ||||
| What is the impact of self-sampling for STIs on linkage to care and case-finding? | GDG. | Acceptability and non-discrimination. | RCT with inclusion of outcomes to measure linkage to care and case-finding. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of effectiveness of the intervention. | Interrupted time series using repeated cross-sectional surveys of populations attending STI clinics for treatment before, during and after implementation of policy to ascertain proportion of women who self-sampled prior to linkage to care. | ||||
| What is the benefit and harm of self-sampling for STIs of viral aetiology? | GDG. | Availability, accessibility and acceptability. | Randomised controlled trial specific to self-collection of STIs of viral aetiology. Outcomes to include measurement of availability and accessibility, as well as acceptability of self-sampling, especially regarding sampling of bloods (eg, hepatitis B virus). | This is a feasible design. | |||||
| Values and preferences | What are the values and preferences of marginalised populations (eg, Men who have sex with men, sex workers, trans populations) regarding self-sampling? | Not applicable. | GDG and survey. | Accessibility acceptability, privacy and confidentiality, and non-discrimination. | Qualitative key informant study of women and men who are marginalised regarding their values and preferences of self-sampling and the barriers that they experience or may experience when accessing self-sampling, receiving their results and when linking to care. | This is a feasible study. | |||
| Human rights and equity | What are the best practices for avoiding coercion in self-sampling? | Not applicable. | GDG. | Non-discrimination, privacy and confidentiality. | Qualitative study using focus groups of vulnerable populations in contexts where self-sampling is implemented to understand how they perceive coercion could be avoided. This can allow creation of an expanded version of the intervention for further evaluation with measurement of non-coercion included as an outcome. | This is a feasible design. | |||
| Resource use | Is self-collection for STIs cost-effective? | Not applicable. | Not applicable. | GDG. | Accessibility. | Modelling studies of cost- effectiveness across broader range of settings, taking both a healthcare provider and societal perspective. | This is a feasible study, but its quality and usefulness depend on the reliability of the parameters for unit costs and effectiveness, which would be drawn from costing studies and the RCTs with effectiveness data. It will also require more long-term modelling to capture downstream effects on linkage to care. | ||
| Does self-collection offer a cost-efficient approach to case detection in low-income settings? | Not applicable. | Not applicable. | GDG. | Availability and accessibility. | Empirical costing studies to estimate the costs and targeting efficiency of self-collection in LMICs using various feasible models of delivery. | As above. | As above. | ||
GDG, Guideline Development Group; GER, gender, equity and human rights; PICO, Population, Interventions, Comparison and Outcomes; RCTs, randomised controlled trials; STI, sexually transmitted infection.
Research gaps for over-the-counter (OTC) oral contraception
| Clinical, programmatic, values-based or human rights question | Current WHO recommendation | Strength of recommendation | Source or quality of evidence | Critical human rights and equity considerations | Ideal study design(s) | Feasibility and practical constraints | Alternative study design | Methodological issues arising in the alternative study design | |
| Benefits versus harms | PICO: should OTC contraception be made available without a prescription? | OTC oral contraception should be made available without a prescription. | Strong. | Very low. | Privacy and confidentiality; accessibility. | RCT conducted in LMIC with inclusion of outcomes to measure accessibility, privacy and confidentiality. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of the effectiveness of the intervention. | Repeated cross-sectional surveys (can be targeted to specific subgroups or of women in the general population including adolescent girls and young women) attending pharmacies to evaluate privacy and confidentiality and choice to obtain OTC contraception over time. | |
| Are there quality differences between OTC oral contraception medication and prescribed oral contraception medication? | Not applicable. | GDG. | Not applicable. | This is a quality assessment concern and requires laboratory analysis and is outside the scope of this article. WHO guidelines for national regulatory authorities exist to guide national regulatory control to ensure substandard products are not made available and that dosages are correct (see | |||||
| What are the optimal ways to provide advice on switching to different oral contraception or using other contraceptive options (eg, via text messaging, in person in pharmacy)? | Not applicable. | GDG. | Accessibility and informed decision making. | Comparative effectiveness research to compare different types of methods to provide advice. | A controlled trial that may or may not be randomised is feasible. Identification or development of modes of health literacy will be required prior to testing in a controlled manner. In LMIC, pharmacy technicians or cashiers may provide advice instead of pharmacists that requires consideration when planning real-world studies. | ||||
| What adverse events arise from providing oral contraception OTC? | Not applicable. | GDG. | Acceptability, informed decision making and non-discrimination. | Convenience sample and cross-sectional survey of women obtaining OTC contraception at pharmacies to elucidate if they have experienced adverse events related to the OTC nature of the contraception. | This is a feasible study design. | Not applicable. | |||
| Values and preferences | What are the values and preferences of women living in low-income and middle-income countries related to OTC oral contraception? | Not applicable. | GDG and survey. | Accessibility, privacy and confidentiality, and non-discrimination. | Qualitative study using key informant interviews with women seeking and/or using contraception and who live in LMIC regarding their values and preferences to elucidate their experiences and observations. A question regarding receipt of appropriate screening for contraindications will be essential to include. | This is a feasible study. | Not applicable. | ||
| Human rights and equity | Will women of all ages be able to access OTC oral contraception? What barriers remain in the healthcare sector? | Not applicable. | GDG. | Availability, accessibility and non-discrimination. | Unannounced standard patient (simulation) study where women of different ages pose as users wishing to procure OTC contraception in different settings, regions and countries. | This is a feasible study design. | While this design is feasible, current obstacles to conducting standard patient research include automated electronic medical records and creation of believable identities. However, this should be less relevant for OTC studies than medical practice studies where simulation is widely used. | ||
| Acceptability | What do healthcare providers know, think and feel about provision of OTC oral contraception, especially in low-income and middle-income settings? | Not applicable. | Survey. | Accessibility, privacy, the right to seek, receive and impart information. | Online global cross-sectional survey of healthcare providers with delivery through relevant organisations. | In many settings of deprivation, and especially in LMIC, online accessibility is limited by costs, inadequate technology and lack of knowledge on how to use tools. | Focus groups in purposively sampled healthcare provider populations and regions. Focus groups are most suitable to drive conversations and elicit responses among participants with shared lived experiences and is less confrontational as the aim is not to gather in-depth personal experiences but assess current cultural and social norms, practices and concerns with respect to OTC contraception. Specific questions can be directed regarding attitudes towards vulnerable populations, for example, trans-men and bisexual women. | ||
| Resource use | Who bears the cost of OTC oral contraception – is the cost shifted from the health system to the user? | Not applicable. | GDG. | Accessibility. | Regional patient costing study using cross-sectional survey of women obtaining OTC contraception at pharmacies to determine 'user cost pathway' (including transport; loss of income) and identify financing sources (eg, user pays, tax-based or contributory health insurance scheme pays). | This is a feasible study. | |||
GDG, Guideline Development Group; PICO, Population, Interventions, Comparison and Outcomes; RCT, randomised controlled trial.
Research gaps for self-sampling for human papilloma virus (HPV) infection
| Clinical, programmatic, values-based or human rights question | Current WHO recommendation | Strength of recommendation | Source or quality of evidence | Key GER considerations | Ideal study design(s) | Feasibility and practical constraints | Alternative study design | Main methodological issues arising in the alternative study design | |
| Benefits versus harms | PICO: should HPV self-sampling be made available to adult women as an additional approach to clinician-based sampling and cervical services? | HPV self-sampling should be made available to adult women as an additional approach to clinician-based sampling and cervical services. | Strong. | Moderate. | No data from LMIC. Availability and accessibility. | RCT conducted in LMIC with inclusion of outcomes to measure availability and accessibility. | As a strong WHO recommendation exists, it would be unethical to repeat an RCT of the effectiveness of the intervention. | Prospective non-controlled cohort study to be conducted in several LMIC where the intervention is or will be implemented. Analysis to combine quantitative survey supplemented with focused in-depth qualitative interviews with women to explore GER outcomes of availability and accessibility. Cost analyses can be nested in the cohort study. | |
| Values and preferences | What is the optimal way(s) to engage women to self-sample, for example, via text or via community-based means? | Not applicable. | GDG. | Accessibility. | Comparative effectiveness research to compare different types of methods to engage women. | A controlled trial that may or may not be randomised is feasible. Identification or development of methods of engagement during a formative stage will be required prior to testing in a controlled manner. Current methods employed in HIV adherence programmes may be informative. | |||
| Human rights and equity | What are the optimal methods to encourage women living in humanitarian settings to self-sample? | Availability, accessibility, acceptability, non-discrimination, privacy and confidentiality | Qualitative key informant study of users in humanitarian settings regarding their experiences of healthcare and desires for self-sampling. | This is a feasible study. | |||||
| How can linkage to care be ensured following HPV self-sampling? | GDG | Accessibility, acceptability and non-discrimination. | Comparative effectiveness research of a package of care that includes self-sampling combined with different strategies such as training of clinic staff to encourage women and facilitate linkage to care compared with self-sampling only. | A controlled trial that may or may not be randomised is a feasible design. Linkage to care needs to include links to care for women self-sampling and sensitisation to HPV vaccination and potential messaging to partners. | |||||
| What are the optimal methods to access homeless women? | Accessibility, acceptability and non-discrimination. | This is an under-researched area. Initial research should include identification of current health-seeking practices of homeless women via qualitative interviews with those working with the homeless and the homeless to find out how they would like to be reached and to develop strategies prior to further evaluation. | This is a feasible design. | ||||||
| Resource use | What is the cost-effectiveness of self-sampling when linkage to care is included as an outcome in the analysis? | Not applicable. | Not applicable. | GDG. | Availability and accessibility. | Modelling studies of cost- effectiveness across broader range of settings, taking both a healthcare provider and societal perspective. | This is a feasible study, but its quality and usefulness depend on the reliability of the parameters for unit costs and effectiveness, which would be drawn from costing studies and the RCTs effectiveness data. It will also require more long-term modelling to capture downstream effects on linkage to care. | ||
| What are the differences in out-of-pocket expenditures for self-sampling between high-income and low-income regions? | Not applicable. | Not applicable. | GDG. | Accessibility. | Empirical costing studies to estimate user and provider costs, and financing sources for each (users pay, or health system pays) | This is a feasible study. | |||
GDG, Guideline Development Group; GER, gender, equity and human rights; PICO, Population, Interventions, Comparison and Outcomes; RCT, randomised controlled trial.
Research gaps for home-based ovulation predictor kits (OPKs)
| Clinical, programmatic, values-based or human rights question | Current WHO recommendation | Strength of recommendation | Source or quality of evidence | Key GER considerations | Ideal study design(s) | Feasibility and practical constraints | Alternative study design | Main methodological issues arising in the alternative study design | |
| Benefits versus harms | PICO: should home-based OPKs be made available as an additional approach to fertility management for women and couples desiring pregnancy? | Home-based OPKs should be made available as an additional approach to fertility management for women and couples desiring pregnancy. | Strong. | Very low. | No data from LMIC. Key GER considerations include availability and accessibility. | RCT conducted in LMIC with inclusion of outcomes to measure availability and accessibility, and exploration of potential for coercion. | As a strong WHO recommendation, it would be unethical to repeat an RCT of the effectiveness of the intervention. | Prospective non-controlled cohort study to be conducted in several LMIC where the intervention is or will be implemented. Analysis to combine quantitative survey supplemented with focused in-depth qualitative interviews with women and partners to explore GER outcomes of availability and accessibility. Exploration of potential for coercion would be advantageous to determine potential harms. Cost analyses can be nested in the cohort study. | |
| How prevalent is infertility in low-income and middle-income settings and what are the consequences? | Not applicable. | GDG. | Not applicable. | Cross-sectional survey of women from general population in LMIC to ascertain self-reported prevalence of infertility. | A large general population survey is feasible but has cost implications to achieve a sufficiently large sample to be representative. | Focused cross-sectional study of women attending primary care clinics, excluding antenatal care, to ascertain self-reported prevalence of infertility. | |||
| What is the impact of using a home-based OPK on communication between partners? | Not applicable. | GDG. | Privacy and confidentiality. | Pharmacy-led survey of women's experiences of partner communication when purchasing the OPK and after using the OPK. | Privacy and perception of lack of privacy, may compromise the integrity of the data and women's willingness to consent to participate. Lack of trained professionals in the pharmacy may also reduce the uptake and quality of the survey. | Qualitative key informant interviews of couples invited to participate either at infertility clinics or at pharmacies. | |||
| Values and preferences | What are the values and preferences of women and men regarding infertility in settings of deprivation (both in high-income countries and in low-income and middle-income countries)? | Not applicable. | GDG. | Non-discrimination. | Online global cross-sectional survey of men and women delivered through relevant organisations. The participants can be any age and infertility is not an inclusion criteria. | In many settings of deprivation, and especially in LMIC, online accessibility is limited by costs, inadequate technology and lack of knowledge on how to use tools. Specific groups, for example, trans men, may not be reached by a survey aimed at the general population. | Focus groups in purposively sampled populations and regions. Focus groups are most suitable to drive conversations and elicit responses among participants with shared lived experiences and is less confrontational as the aim is not to gather in-depth personal experiences of infertility, but assess current cultural and social norms. Recruitment of specific groups, for example, trans men, can be targeted appropriately. | ||
| Resource use | Are home-based OPKs cost-effective compared with other fertility management options? | Not applicable. | GDG. | Availability and accessibility. | Modelling studies of cost-effectiveness. | This is a feasible study design. Modelling will require identification of secondary data on the costs of OPK and other fertility management options in a specific country setting. Assumptions underlying the model will include selection of a primary outcome (pregnancy or live birth) or disability-adjusted life years or quality-adjusted life years (which can capture reduced disability or improved quality of life from reduction in anxiety). Assessment and incorporation of human rights measurements such as privacy and non-coercion will be challenging. Any modelling will either need to be country-specific or stratified by country. | |||
GDG, Guideline Development Group; GER, gender, equity and human rights; PICO, Population, Interventions, Comparison and Outcomes; RCT, randomised controlled trial.